Stock News & Analysis

Another day, another price target reduction.

AI disruption fears collided with hawkish Fed comments, sending financial stocks into a tailspin.

The leader of consumer hardware and software is posting impressive growth these days.

Lenders begin to worry about how AI agents could undermine their borrowers.

Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.

The stock has been volatile as it is set to report Q4 earnings.

Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.

NuScale Power develops modular nuclear reactors for clean energy; a key insider recently trimmed their indirect stake, SEC filings show.

Will AI agents crash the U.S. economy?

Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions.

Polymarket bettors are bullish on Home Depot.

Tencent Music remains central to China’s shift from free streaming to paid listening, despite Keystone Investors selling its stake in the fourth quarter. The company is focusing more on subscription revenue and is moving away from its roots in virtual gifting and social entertainment. The main question is whether this change will lead to more stable earnings as the market develops.

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

Prediction markets like Kalshi have attracted significant interest, especially in recent years.

Social Security may become even less reliable.

Micron and The Trade Desk are still reliable long-term investments.

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

Investors continue to fret whether the company has bitten off more than it can chew with its AI-spending commitments.

Even around all-time highs, these exchange-traded funds (ETFs) are great buys for value investors.